Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
Tweet Send to a Friend
Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
